141 related articles for article (PubMed ID: 31598748)
1. MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer.
Lampropoulou DI; Aravantinos G; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
Int J Colorectal Dis; 2019 Nov; 34(11):1871-1877. PubMed ID: 31598748
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer.
Lampropoulou DI; Aravantinos G; Katifelis H; Lazaris F; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
Cancer Biomark; 2019; 25(2):213-221. PubMed ID: 31045514
[TBL] [Abstract][Full Text] [Related]
3. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
Treenert A; Areepium N; Tanasanvimon S
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
[TBL] [Abstract][Full Text] [Related]
4. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Boni V; Zarate R; Villa JC; Bandrés E; Gomez MA; Maiello E; Garcia-Foncillas J; Aranda E
Pharmacogenomics J; 2011 Dec; 11(6):429-36. PubMed ID: 20585341
[TBL] [Abstract][Full Text] [Related]
5. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population.
Danesh H; Hashemi M; Bizhani F; Hashemi SM; Bahari G
Gene; 2018 Mar; 647():73-78. PubMed ID: 29317318
[TBL] [Abstract][Full Text] [Related]
6. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Lonardi S; Bergamo F; Ning Y; Yamamoto N; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Stintzing S; Heinemann V; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2018 Sep; 18(5):623-632. PubMed ID: 29925895
[TBL] [Abstract][Full Text] [Related]
7. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
8. UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Yu Q; Zhang T; Xie C; Qiu H; Liu B; Huang L; Peng P; Feng J; Chen J; Zang A; Yuan X
Cancer Chemother Pharmacol; 2018 Jul; 82(1):87-98. PubMed ID: 29728798
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Association Between miR-608 rs4919510 and miR-149 rs2292832 with Colorectal Cancer in Iranian Population.
Ranjbar R; Chaleshi V; Aghdaei HA; Morovvati S
Microrna; 2018; 7(2):100-106. PubMed ID: 29412127
[TBL] [Abstract][Full Text] [Related]
10. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
12. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.
Wu C; Li M; Hu C; Duan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):335-41. PubMed ID: 24288122
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
[TBL] [Abstract][Full Text] [Related]
15. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
16. Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Aravantinos G; Isaakidou A; Karantanos T; Sioziou A; Theodoropoulos GE; Pektasides D; Gazouli M
Cancer Biomark; 2015; 15(6):843-50. PubMed ID: 26406410
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
[TBL] [Abstract][Full Text] [Related]
18. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK; Antonacopoulou AG; Eleftheraki AG; Dimitrakopoulos FI; Koumarianou A; Varthalitis I; Fostira F; Sgouros J; Briasoulis E; Bournakis E; Bafaloukos D; Bompolaki I; Galani E; Kalogeras KT; Pectasides D; Fountzilas G; Kalofonos HP
Pharmacogenomics J; 2012 Dec; 12(6):468-75. PubMed ID: 21844885
[TBL] [Abstract][Full Text] [Related]
20. Pre-miRNA variants as predictors of clinical outcome in patients with squamous cell carcinomas of the nonoropharynx.
Wang C; Sturgis EM; Chen X; Zheng H; Wei Q; Li G
Oncotarget; 2016 May; 7(18):26444-53. PubMed ID: 27050146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
